Dataset Information

Silver Nanoparticles Combined With Naphthoquinones as an Effective Synergistic Strategy Against Staphylococcus aureus.

ABSTRACT: Staphylococcus aureus is a human pathogen responsible for many antibiotic-resistant infections, for instance burn wound infections, which pose a threat to human life. Exploring possible synergy between various antimicrobial agents, like nanoparticles and plant natural products, may provide new weapons to combat antibiotic resistant pathogens. The objective of this study was to examine the potential of silver nanoparticles (AgNPs) to enhance the antimicrobial activity of selected naphthoquinones (NQs): plumbagin (PL), ramentaceone (RAM), droserone (DR), and 3-chloroplumbagin (3ChPL). We also attempted to elucidate the mechanism by which the AgNPs enhance the antimicrobial activity of NQs. We analyzed the interaction of AgNPs with bacterial membrane and its effect on membrane stability (TEM analysis, staining with SYTO9 and propidium iodide), as well as aggregation of NQs on the surface of nanoparticles (UV-Vis spectroscopy and DLS analysis). Our results demonstrated clearly a synergistic activity of AgNPs and three out of four tested NQs (FBC indexes ≤ 0.375). This resulted in an increase in their combined bactericidal effect toward the S. aureus reference strain and the clinical isolates, which varied in resistance profiles. The synergistic effect (FBC index = 0.375) resulting from combining 3ChPL with silver nitrate used as a control, emphasized the role of the ionic form of silver released from nanoparticles in their bactericidal activity in combination with NQs. The role of membrane damage and AgNPs-NQ interactions in the observed synergy of silver nanoparticles and NQs was also confirmed. Moreover, the described approach, based on the synergistic interaction between the above mentioned agents enables a reduction of their effective doses, thus significantly reducing cytotoxic effect of NQs toward eukaryotic HaCaT cells. Therefore, the present study on the use of a combination of agents (AgNPs-NQs) suggests its potential use as a possible strategy to combat antibiotic-resistant S. aureus.

SUBMITTER: Krychowiak M

PROVIDER: S-EPMC6094968 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:The chemotherapeutic options for methicillin-resistant Staphylococcus aureus (MRSA) infections are limited. Due to the multiple resistant MRSA, therapeutic failure has occurred frequently, even using antibiotics belonging to different categories in clinical scenarios, very recently. This study aimed to investigate the interactions between 11 antibiotics representing different mechanisms of action against MRSA strains and provide therapeutic strategies for clinical infections. Susceptibilities for MRSA strains were determined by broth microdilution or agar dilution according to CLSI guideline. By grouping with each other, a total of 55 combinations were evaluated. The potential synergism was detected through drug interaction assays and further investigated for time-killing curves and an in vivo neutropenic mouse infection model. A total of six combinations (vancomycin with rifampicin, vancomycin with oxacillin, levofloxacin with oxacillin, gentamycin with oxacillin, clindamycin with oxacillin, and clindamycin with levofloxacin) showed synergistic activity against the MRSA ATCC 43300 strain. However, antibacterial activity against clinical isolate #161402 was only observed when vancomycin combined with oxacillin or rifampicin in time-killing assays. Next, therapeutic effectiveness of vancomycin/oxacillin and vancomycin/rifampicin was verified by an in vivo mouse infection model inoculated with #161402. Further investigations on antimicrobial synergism of vancomycin plus oxacillin and vancomycin plus rifampicin against 113 wild-type MRSA strains were evidenced by combined antibiotic MICs and bacterial growth inhibition and in vitro dynamic killing profiles. In summary, vancomycin/rifampicin and vancomycin/oxacillin are the most potential combinations for clinical MRSA infection upon both in vitro and in vivo tests. Other synergetic combinations of levofloxacin/oxacillin, gentamycin/oxacillin, clindamycin/oxacillin, and clindamycin/fosfomycin are also selected but may need more assessment for further application.

Dataset Information

Silver Nanoparticles Combined With Naphthoquinones as an Effective Synergistic Strategy Against Staphylococcus aureus.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets